BC Innovations | May 15, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Mouse studies suggest a fusion protein-based vaccine plus a STING-activating cyclic dinucleotide (CDN) adjuvant could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA, hrp1, rpfD and...
BC Innovations | Feb 6, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Non-human primate studies suggest a vaccine based on cytomegalovirus (CMV) expressing six M. tuberculosis antigens could help prevent tuberculosis (TB). The vaccine consists of six bacterial antigens -- M. tuberculosis fbpA, esxA, vapB47,...
BC Innovations | Mar 2, 2017
Translation in Brief

Polyester protection

A vaccine based on engineered biobeads offers a new paradigm for immunization against tuberculosis that incorporates both known and unknown antigens to mimic the broad repertoire of live vaccines, but with the safety of non-infectious...
BC Week In Review | Nov 18, 2013
Clinical News

AERAS-456: Phase I/IIa started

Not-for-profit Aeras and the Danish government institute said the South African Tuberculosis Vaccine Initiative (SATVI) began a 2-part, double-blind, South African Phase I/IIa trial to evaluate 3 doses of AERAS-456 containing 5, 15 or 50...
BC Week In Review | Jan 16, 2012
Clinical News

Tuberculosis vaccine: Phase II started

Intercell said Statens Serum Institut (Copenhagen, Denmark) began a double-blind, South African and Tanzanian Phase II trial to evaluate 2 doses of H1IC in HIV-infected patients. The European and Developing Countries Clinical Trials Partnership (EDCTP)...
BC Innovations | Feb 17, 2011
Targets & Mechanisms

Protecting against latent TB

A team of EU and U.S. researchers has created a subunit vaccine based on three Mycobacterium tuberculosis antigens and shown that it protects healthy mice from tuberculosis and prevents reactivation of disease in mouse models...
BC Innovations | Feb 3, 2011
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis (TB) Mycobacterium tuberculosis Rv2660c hypothetical protein (Rv2660c); M. tuberculosis secreted antigen 85-B (fbpB; Ag85B); M. tuberculosis 6 kDa early...
BC Innovations | Mar 5, 2009
Targets & Mechanisms

Subunit boost for TB vaccines

A long-term study in macaques by GlaxoSmithKline plc and collaborators bolsters the case for using a subunit tuberculosis vaccine to boost the effects of the only marketed TB prophylactic-bacille Calmette-Guérin (BCG). 1 Ongoing Phase I...
BC Week In Review | Mar 19, 2007
Clinical News

Tuberculosis: Preliminary Phase I data

Preliminary data from an open-label, Dutch Phase I trial in 36 healthy volunteers showed that ICLL's TB vaccine was safe and stimulated a strong immunogenic T cell response. Intercell AG (VSE:ICLL), Vienna, Austria   Product:...
Items per page:
1 - 9 of 9